Pulmonary Aspergillosis: Therapeutic Management and Prognostic Factors from 16 Years of Monocenter Experience
- 22 June 2012
- book chapter
- Published by Springer Science and Business Media LLC in Advances in experimental medicine and biology
- Vol. 755, 225-236
- https://doi.org/10.1007/978-94-007-4546-9_29
Abstract
Twenty three patients of the University Hospital Bonn were reviewed following surgical procedures for pulmonary aspergilloma, including the choice of antifungal therapy, diagnostic findings, decision-making in treatment, and treatment outcomes of the past 16 years. We used pathological records to identify aspergilloma patients. A review of patients’ records and follow-up phone calls to patients, families, or general practitioners were done. Data collected from 1995 to 2011 included patients with aspergilloma (n = 15), multiple aspergillomas (n = 2) and chronic necrotizing pulmonary aspergillosis (n = 6). Classification and diagnosis were based on pathological records. The decision to use systemic antimycotic therapy was based on perioperative findings suspecting parenchymal involvement of the fungal infection. Seventeen patients received systemic antimycotic chemotherapy. Compared with the use of Amphotericin B, newer drugs such as voriconazol, caspofungin, or posaconazol showed no better result in the morbidity and mortality of the patients. Postoperative complications requiring extended therapy and/or prolonged ICU stay (>48 h) were seen in 12 (52.2%) patients. During follow-up there were ten deaths; one death (4.4%) from aspergillus-associated sepsis, nine deaths from patients’ underlying diseases (n = 4 within 3 months of follow-up). In conclusion, in our cohort, immunocompromised patients with no documented preexisting lung-cavities were most likely to develop pulmonary aspergilloma. Postoperative morbidity (52.2%) was high, but related mainly to patient co-morbidity; postoperative mortality was reasonably low. Patients showing classical symptoms or immunocompromised patients should be considered for surgery. Encapsulated Aspergilloma without invasion of surrounding parenchyma requires no antifungal chemotherapy.Keywords
This publication has 34 references indexed in Scilit:
- Chirurgie des aspergillomes pulmonairesLa Presse Médicale, 2006
- Die chirurgische Therapie des pulmonalen AspergillomsMycoses, 2005
- Good Long-Term Outcomes After Surgical Treatment of Simple and Complex Pulmonary AspergillomaThe Annals of Thoracic Surgery, 2005
- Antikörper‐Nachweis bei invasiver AspergilloseMycoses, 2004
- Management of Invasive Pulmonary Aspergillosis in Hematology Patients: A Review of 87 Consecutive Cases at a Single InstitutionClinical Infectious Diseases, 2000
- Surgery for pulmonary aspergillosisEuropean Journal of Cardio-Thoracic Surgery, 1997
- Percutaneous Intracavitary Antifungals for a Patient with Pulmonary Aspergilloma; with a Special Reference to in vivo Efficacies and in vitro Susceptibility Results.Internal Medicine, 1995
- Surgery for Pulmonary Aspergilloma and Pleural AspergillosisThe Thoracic and Cardiovascular Surgeon, 1988
- Surgical Treatment of Pulmonary AspergillomaAnnals of Surgery, 1977